An evaluation of the in vitro activity of terbinafine

Medical Mycology

Volumn 38, Issue 2, 2000, Pages 155-159

  Jessup, C J ^a   Ryder, N S ^b   Ghannoum, M A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

In vitro susceptibility; Terbinafine

Indexed keywords

TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTE; DILUTION; HOST SUSCEPTIBILITY; IC 50; IN VITRO STUDY; NONHUMAN; TRICHOSPORON BEIGELII;

ARTHRODERMATACEAE; ASPERGILLUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANIS; EPIDERMOPHYTON FLOCCOSUM; FILOBASIDIELLA NEOFORMANS; FUNGI; FUSARIUM; ISSATCHENKIA ORIENTALIS; MICROSPORUM CANIS; SPOROTHRIX; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS; TRICHOSPORON BEIGELII;

EID: 0033999792     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/714030927     Document Type: Article

References (31)

1. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-287.
2. Ryder NS, Mieth H. Allylamine antifungal drugs. Curr Top Med Mycol 1992; 4: 158-188.
3. Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057-1061.
4. Arzeni D, Barchiesi F, Compagnucci P, et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. Medical Mycology 1998; 36: 235-237.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. Wayne. PA: National Committee for Clinical Laboratory Standards, 1997.
6. Clayton YM. The in vitro activity of terbinafine against uncommon fungal pathogens. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal agents. Barcelona: J.R. Prous Science Publishers, 1987: 433-439.
7. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7-8.
8. Goudard M, Cordier C, Regli P. Sensibilité des Fusarium aux antifongiques: essais in vitro. Bull Soc Fr Mycol Med 1988a; 17: 199-202.
9. Rubio MC, Gil J, Rezusta A, Bueno MR, Bueno R. In vitro evaluation of three new antifungal agents: amorolfine (Ro 14-4767/002), terbinafine (SF 86-327) and itraconazole (R 51,211). Rev Esp Quimioterap 1993; 6: 125-139.
10. Venugopal PV, Venugopal TV. Antifungal activity of allylamine derivatives. Indian J Med Res 1994; 99: 71-73.
11. Meingassner JG, Frei R, Leitner I. Activity of terbinafine against isolates of Paecilomyces lilacinus resistant to amphotericin B, miconazole, fluconazole and itraconazole. Second International Summit on Cutaneous Antifungal Therapy, Boston, November 11-13, 1994. Cleveland, OH: Case Western Reserve University, 1994: Abstract 15.
12. Shadomy S, Espinell-Ingroff A, Gebhart RJ. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985; 23: 125-132.
13. Ahmad A, Khan AK, Sultana S, Siddiqi SA, Haroon TS. In vitro antifungal studies of terbinafine. Pakistan J Sci Ind Res 1989; 32: 737-739.
14. Goudard M, Buffard Y, Ferrari H, Regli P. Spectre d'action in vitro d'un nouvel antifungique derive de la naftifine: la terbinafine (SF 86-327). Pathol Biol (Paris) 1986; 34: 680-683.
15. Hiratani T, Asagi Y, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol 1991; 32: 323-332.
16. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365-1368.
17. Bryan CS, Smith CW, Berg DE, Karp RB. Curvularia lunata endocarditis treated with terbinafine-case report. Clin Infect Dis 1993; 16: 30-32.
18. Goudard M, Regli P, Buffard Y, Gabriel B. Sensibilité in vitro des Aspergillus a la terbinafine: étude comparative avec l'amphotericine B, la 5-fluorocytosine et le ketoconazole. Pathol Biol (Paris) 1988b; 36: 129-143.
19. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780-781.
20. Wong PK, Ching WTW, Kwon-Chung KJ, Meyer RD. Disseminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis 1989; 11: 770-775.
21. Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasin S. Antifungal activity of allylamines against agents of eumycetoma. Indian J Dermatol Venereal Leprol 1993; 59: 239-242.
22. Polak A, Dixon DM. Loss of melanin in Wangiella dermatiditis does not result in greater susceptibility to antifungal agents. Antimicrob Agents Chemother 1989; 33: 1639-1640.
23. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987; 33: 129-140.
24. De Hoog GS, Matsumoto T, Matsuda T, Uijthof JMJ. Exophiala jeanselmei var. lecanii-corni, an etiologic agent of human phaeohyphomycosis, with report of a case. J Med Vet Mycol 1994; 32: 373-380.
25. Venugopal PV, Venugopal TV. Disk diffusion susceptibility testing of dermatophytes with allylamines. Int J Dermatol 1994; 33: 730-732.
26. Butty P, Lebecq JC, Mallie M, Bastide JM. Evaluation of the susceptibility of dermatophytes to antifungal drugs: a new technique. J Med Vet Mycol 1995; 33: 403-409.
27. th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, 15-18 September 1996. Washington DC: American Society for Microbiology, 1996: Abstract E54.
28. Jensen JC. Clinical pharmacokinetics of terbinafine. Clin Exp Dermatol 1989; 14: 110-114.
29. Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992; 126 (Suppl. 39): 8-13.
30. Ryder NS, Dupont. MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 1985; 230: 765-770.
31. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual Framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-247.